COHANCE.NS Balance Sheet
Cohance Lifesciences Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:43
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹584.19 Cr. | ₹567.22 Cr. | ₹995.20 Cr. | ₹1,990.08 Cr. | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹165.09 Cr. | ₹178.97 Cr. | ₹254.83 Cr. | ₹173.22 Cr. | CapitalWorkInProgress |
| Goodwill | ₹0.00 Cr. | ₹0.00 Cr. | ₹655.11 Cr. | ₹1,283.65 Cr. | Goodwill |
| Other Intangible Assets | ₹79.14 Cr. | ₹102.40 Cr. | ₹63.11 Cr. | ₹95.01 Cr. | OtherIntangibleAssets |
| Non-current Investments | ₹117.10 Cr. | ₹130.58 Cr. | ₹144.95 Cr. | ₹262.23 Cr. | NoncurrentInvestments |
| Other Non-current Assets | ₹3.25 Cr. | ₹2.24 Cr. | ₹5.48 Cr. | ₹56.62 Cr. | OtherNoncurrentAssets |
| Total Non-current Assets | ₹954.70 Cr. | ₹990.90 Cr. | ₹2,143.16 Cr. | ₹3,901.68 Cr. | NoncurrentAssets |
| Inventories | ₹312.81 Cr. | ₹231.20 Cr. | ₹166.57 Cr. | ₹562.23 Cr. | Inventories |
| Trade Receivables | ₹110.94 Cr. | ₹133.66 Cr. | ₹284.44 Cr. | ₹681.01 Cr. | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹64.80 Cr. | ₹47.23 Cr. | ₹85.40 Cr. | ₹49.14 Cr. | CashAndCashEquivalents |
| Current Investments | ₹418.94 Cr. | ₹773.90 Cr. | ₹191.74 Cr. | ₹266.32 Cr. | CurrentInvestments |
| Other Current Assets | ₹99.87 Cr. | ₹62.69 Cr. | ₹111.47 Cr. | ₹217.17 Cr. | OtherCurrentAssets |
| Total Current Assets | ₹1,011.05 Cr. | ₹1,263.19 Cr. | ₹853.28 Cr. | ₹1,796.26 Cr. | CurrentAssets |
| Total Assets | ₹1,965.74 Cr. | ₹2,254.09 Cr. | ₹3,031.75 Cr. | ₹5,729.64 Cr. | Assets |
| Equity Share Capital | ₹25.46 Cr. | ₹25.46 Cr. | ₹25.46 Cr. | ₹38.26 Cr. | EquityShareCapital |
| Other Equity | ₹1,709.73 Cr. | ₹2,025.21 Cr. | ₹1,671.12 Cr. | ₹3,873.03 Cr. | OtherEquity |
| Equity Attributable to Owners | ₹1,735.18 Cr. | ₹2,050.66 Cr. | ₹1,696.58 Cr. | ₹3,911.29 Cr. | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | N/A | N/A | ₹144.06 Cr. | ₹122.54 Cr. | NonControllingInterest |
| Total Equity | ₹1,735.18 Cr. | ₹2,050.66 Cr. | ₹1,840.64 Cr. | ₹4,033.83 Cr. | Equity |
| Long-term Borrowings | ₹4.56 Cr. | ₹0.00 Cr. | ₹6.24 Cr. | ₹50.48 Cr. | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹71.79 Cr. | ₹96.53 Cr. | ₹825.92 Cr. | ₹1,049.88 Cr. | NoncurrentLiabilities |
| Short-term Borrowings | ₹64.60 Cr. | ₹38.58 Cr. | ₹71.89 Cr. | ₹119.19 Cr. | BorrowingsCurrent |
| Trade Payables | ₹65.16 Cr. | ₹42.36 Cr. | ₹80.21 Cr. | ₹284.58 Cr. | TradePayablesCurrent |
| Other Current Liabilities | ₹2.95 Cr. | ₹7.20 Cr. | ₹7.07 Cr. | ₹59.43 Cr. | OtherCurrentLiabilities |
| Total Current Liabilities | ₹158.77 Cr. | ₹106.90 Cr. | ₹365.19 Cr. | ₹645.93 Cr. | CurrentLiabilities |
| Total Equity and Liabilities | ₹1,965.74 Cr. | ₹2,254.09 Cr. | ₹3,031.75 Cr. | ₹5,729.64 Cr. | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from COHANCE.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).